10x Genomics (1KJ) Stock Overview
Develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1KJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.10 |
| 52 Week High | US$22.14 |
| 52 Week Low | US$7.02 |
| Beta | 2.05 |
| 1 Month Change | 16.39% |
| 3 Month Change | 34.66% |
| 1 Year Change | 195.37% |
| 3 Year Change | -54.99% |
| 5 Year Change | -85.94% |
| Change since IPO | -61.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KJ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 15.8% | 11.9% | 3.2% |
| 1Y | 195.4% | -10.8% | 2.5% |
Return vs Industry: 1KJ exceeded the German Life Sciences industry which returned -10.8% over the past year.
Return vs Market: 1KJ exceeded the German Market which returned 2.5% over the past year.
Price Volatility
| 1KJ volatility | |
|---|---|
| 1KJ Average Weekly Movement | 10.8% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.3% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1KJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1KJ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,178 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
10x Genomics, Inc. Fundamentals Summary
| 1KJ fundamental statistics | |
|---|---|
| Market cap | €2.59b |
| Earnings (TTM) | -€19.52m |
| Revenue (TTM) | €550.38m |
Is 1KJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KJ income statement (TTM) | |
|---|---|
| Revenue | US$638.78m |
| Cost of Revenue | US$193.67m |
| Gross Profit | US$445.11m |
| Other Expenses | US$467.77m |
| Earnings | -US$22.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 69.68% |
| Net Profit Margin | -3.55% |
| Debt/Equity Ratio | 0% |
How did 1KJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 14:47 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
10x Genomics, Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |